Full-Time

Senior Medical Director / Medical Director

Pharmacovigilance

Posted on 6/5/2025

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops base editing–based precision medicines

Compensation Overview

$210k - $375k/yr

Cambridge, MA, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
SAS
Risk Management
Requirements
  • MD required, Board certification preferred with 15+ years of experience
  • 5+ years of pharmacovigilance experience; other relevant experience may be considered
  • Experience in cell or gene therapy preferred; experience in other serious conditions, including oncology, rare or fatal conditions will be considered
  • Oversight experience of global medical safety activities including asset / approved product level safety governance, operations and risk management strategies in pre and post marketing environments
  • Demonstrated knowledge of global pharmacovigilance regulatory environment with working knowledge of international regulations including but not limited to FDA, EMA, ICH guidelines and regulations pertaining to clinical development and post-marketing safety environments
  • Working knowledge of industry standard safety databases (ARGUS and ARISg) and other electronic data capture systems
  • Knowledge of MedDRA dictionary with relevance to adverse event coding
  • Excellent knowledge of drug development process, including clinical trial methodology, medical terminology and general principles of clinical assessment of adverse events
  • Experience reviewing cumulative safety data with ability to interpret, synthesize and communicate complex clinical /pharmaceutical information and safety data and developing risk management/mitigation strategies
  • Experienced in supporting health authority interactions, both written and verbal
  • Ability to navigate fast-paced and dynamic work environment; ability to manage and prioritize multiple projects and demands simultaneously with ability to adjust to changing priorities and work effectively under pressure; organizational and prioritization skills a must
  • Demonstrates leadership and interacts collaboratively and effectively in a team environment (e.g. Clinical Operations, Clinical Science, Data Management, Medical Affairs) and with external vendors and stakeholders
  • Excellent organizational skills, sufficient to multi-task in an extremely fast-paced environment with changing priorities
  • Excellent leadership and communication skills with ability to influence at all levels of the organization
  • International/domestic travel may be required
Responsibilities
  • Provide dynamic leadership, strategic direction and governance of patient safety and PV risk management activities across Beam’s portfolio
  • Lead signal detection and risk management activities for assigned products including individual and aggregate data analyses, preparing signal assessment, tracking and validation documents; lead cross functional teams to analyze and interpret safety data; preparing action and communication plans (written and verbal) to mitigate/manage product risks, in collaboration with key stakeholders
  • Lead proactive and ongoing analysis and interpretation of non-clinical data, clinical, post-marketing, scientific literature and other sources to establish the risk profile for products early in development, with ongoing assessment of benefit-risk and update of benefit-risk documents throughout the lifecycle of assigned products
  • Lead PV during interactions with Regulatory Authorities (RA), including authoring and review of regulatory meeting materials, addressing questions from RAs, and attending meetings as the PV subject matter expert (SME) during RA interactions
  • Perform individual case safety report (ICSR) medical review to ensure accurate medical coding, seriousness, expectedness and company causality assessment, ensure appropriate medical interpretation, completeness, and accuracy of information, review and draft queries, and prepare or review the analysis of similar events (AOSE) as required
  • Lead multidisciplinary Safety Management Committee (SMC) and Executive Safety Committee (ESC) whose responsibilities include safety surveillance (signal detection and evaluation), risk management planning, and making recommendations regarding risk assessment, communication plan and labeling, as appropriate
  • Serve as PV SME in support of regulatory filing activities (e.g. BLA) for assigned product(s) to develop the safety strategy, author/review safety-related content, participate in filing preparation meetings and deliverables, and support labeling activities
  • Collaborate with cross functional team, including Clinical Development, Regulatory Affairs, Biostatistics, and other functional areas to design, evaluate, implement, and oversee safety risk mitigation strategies (REMS, Risk Management Plan, Post-Approval Safety Surveillance) to ensure safe and appropriate use of company products in compliance with global regulatory requirements
  • Address internal/external safety-related requests, including questions from Health Authorities, Ethics Committees, Data Monitoring Committees, Safety Review Committees (both written and verbal)
  • Provide guidance regarding Statistical Analysis Plans and format of safety data for analyses e.g. tables, listings
  • Author and/or review pre- and post-marketing aggregate safety reports including DSUR, 6-monthly line listing reports, PSUR, PBRER, PADER, IND Annual Reports
  • Provide PV expertise to support full lifecycle drug development and study execution; represent PV at study execution and strategic forums
  • Support and/or serve as PV SME during inspection readiness activities, internal audits, and external inspections
  • Develops expertise in gene editing, with continuous knowledge acquisition and education regarding current safety matters relating to gene editing
  • Develop training materials and conduct training on PV related content, including presentations at Investigator Meetings or Site Initiation Visits, as needed
  • Review medical/scientific literature to support signal detection activities and aggregate reporting for products
  • Contribute to the development and review of clinical, regulatory, and scientific documents including protocols, informed consent forms, clinical study reports, external manuscripts/journal articles/publications, case report forms, statistical analysis plans, integrated summaries of safety (ISS), New Drug or Biologic License Applications (NDA/BLA), and/or other documents as needed, ensuring safety content and messaging is harmonized where applicable
  • Lead/contribute to safety data analyses, messaging and presentations for DMC meetings
  • Develop or support development of standard operating procedures (SOPs) and/or other process related documents e.g. Safety Management Plans, Work Instructions
  • Contribute to vendor governance activities and oversight of key performance indicators
  • Lead and/or contribute to the development and maintenance of Reference Safety Information (RSI) including Company Core Data Sheet (CCDS), Company Core Safety Information (CCSI), Investigator Brochure (IB), and/or other product labeling
  • Participates in MedDRA and WHODrug coding and SAE reconciliation activities
  • Participate in the development of PV organizational strategy, goals, and objectives and assist with implementation and training to support department goals and initiatives
  • Maintain knowledge of new PV/safety regulations and guidance from regulatory authorities, BEAM SOPs, and quality standards
  • Maintain knowledge of disease indications for assigned products (full lifecycle)
  • Support hiring, orientation, management, mentorship, and development of PV team
  • Support organizational leadership in assigned activities and initiatives
  • Maintain knowledge of disease indications for assigned Beam products
  • Other duties, as assigned
Desired Qualifications
  • Experience in cell or gene therapy preferred

Beam Therapeutics uses base editing to develop precision genetic medicines aimed at correcting disease-causing mutations. It focuses on R&D and collaborates with pharmaceutical companies and research institutions to fund and advance therapies, earning revenue through partnerships, licensing, upfront and milestone payments, and royalties. The company targets genetic disorders such as sickle cell disease with the goal of delivering lifelong cures, differentiating itself through its emphasis on durable genetic remedies and a science-driven, values-led culture.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • BEAM-302 achieves clinical proof-of-concept in alpha-1 antitrypsin deficiency Phase 1/2 trial.
  • $500M Sixth Street credit facility funds risto-cel sickle cell launch by 2027.
  • BEACON trial data for BEAM-101 in 17 sickle cell patients presented at EHA2025.

What critics are saying

  • CRISPR Therapeutics' Casgevy captures 70% sickle cell market share since December 2024.
  • Busulfan conditioning toxicity halts BEAM-101 trial per EHA2025 data.
  • Prime Medicine's prime editing outperforms base editing in AATD models per October 2025.

What makes Beam Therapeutics unique

  • Beam's base editors precisely convert single DNA bases without double-strand breaks.
  • Proprietary cytosine and adenine editors target point mutations in genetic diseases.
  • Founded in 2017 by Harvard base editing pioneers for precision genetic medicines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Yahoo Finance
Apr 11th, 2026
Beam Therapeutics CEO sells 30,000 shares worth $739K under trading plan

Beam Therapeutics CEO John Evans sold 30,078 shares on 1 April 2026 for approximately $739,000, according to an SEC Form 4 filing. The shares were sold at around $24.58 each under a pre-established Rule 10b5-1 trading plan. This sale is smaller than Evans' recent average of 45,200 shares per transaction and represents his smallest open-market sale in his last four disclosed transactions. Following the sale, Evans retains 1,047,205 direct shares and 103,000 indirect shares, maintaining direct ownership of 1.03% of outstanding shares. Beam Therapeutics, valued at $2.79 billion, develops precision genetic medicines using base editing technology, focusing on treatments for sickle cell disease, beta thalassemia and other rare genetic disorders.

pharmaphorum
Apr 10th, 2026
Chinese trial backs base-editing drug for thalassaemia.

Chinese trial backs base-editing drug for thalassaemia. digitale.de A landmark study in China has shown that a base-editing therapy developed by CorrectSequence Therapeutics achieved stellar results in patients with the severe blood disorder beta-thalassaemia. The ex vivo therapy, CS-101, has been tested in an investigator-led trial in five patients with transfusion-dependent beta-thalassemia who received autologous CD34 stem cells modified with the base editor to reactivate the production of a foetal form of haemoglobin. In beta-thalassaemia, mutations in the beta-globin gene mean that patients have deficient production of the adult form of haemoglobin. In severe cases, they have to have blood transfusions every two to five weeks to survive, a burdensome treatment that also places them at risk of complications like iron overload and infections. In the trial, all five patients were able to discontinue transfusions after a single infusion of CS-101-modified stem cells, with rapid and sustained increases in haemoglobin levels over three months of follow-up. Remarkably, patients became transfusion-independent within an average of just 16 days, according to the researchers, who have published their findings in the journal Nature. Shanghai-based CorrectSequence is one of the pioneers of the base-editing approach to gene-editing, which can be used to convert one nucleotide base into another without cutting both strands of DNA, unlike other technologies like CRISPR/Cas9. Theoretically, base-editing should be more accurate and have a reduced risk of off-target changes that could cause side effects. CorrectSequence said that, compared to CRISPR-based therapies for beta-thalassaemia, CS-101 demonstrated "faster activation of foetal haemoglobin, more rapid hematopoietic recovery, and earlier restoration of normal haemoglobin levels." The only gene-editing therapy approved for beta-thalassaemia at present is Vertex Pharma's CRISPR-based Casgevy (exagamglogene autotemcel), which has been cleared in the US and Europe for patients aged 12 and older with transfusion-dependent beta-thalassaemia who lack a suitable donor for stem cell transplant. Donor stem cell transplantation was the only curative option for patients for many years, but its use is limited by donor availability, the risk of immune rejection, and high treatment costs, said CorrectSequence. The company thinks CS-101 - which has now been used to treat around 20 patients in the US and internationally - has the potential to become the world's first approved base-editing therapy. Last year, it also reported encouraging clinical results in a patient with chylomicronaemia treated with its CS-121 base editor targeting the APOC3 gene. Other companies working on base-editing technologies include Beam Therapeutics of the US, which is developing a similarly acting ex vivo therapy for sickle cell disease (SCD), called ristoglogene autogetemcel, that showed efficacy in a phase 1/2 trial published in the New England Journal of Medicine earlier this month and could be submitted for FDA approval before the end of the year.

MarketScreener
Feb 24th, 2026
Beam Therapeutics secures $500M credit facility with Sixth Street for sickle cell treatment launch

Beam Therapeutics has secured a $500 million senior secured credit facility with Sixth Street to support the anticipated launch of ristoglogene autogetemcel (risto-cel) for sickle cell disease. The agreement includes $100 million funded at close, up to $300 million available upon clinical, regulatory and commercial milestones, and an additional $100 million at Beam's option. The facility has a seven-year term maturing in early 2033, with an annual interest rate of approximately 10% based on SOFR. No scheduled amortization payments are required, with all principal due at maturity. Beam expects to draw at least $200 million under the facility. The financing provides non-dilutive capital to support risto-cel's commercialisation whilst allowing Beam to direct resources towards pipeline growth and developing precision genetic medicines.

Sahm Capital
Dec 19th, 2025
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Beam Therapeutics to present at 44th Annual J.P. Morgan Healthcare Conference. Beam Therapeutics +1.33% CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San Francisco. The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Holly Manning Beam Therapeutics [email protected] This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

NetworkNewsWire
May 23rd, 2025
Networknewsbreaks - Beam Therapeutics Inc. (Nasdaq: Beam) To Present New Sickle Cell Data From Beacon Trial At Eha2025

Beam Therapeutics (NASDAQ: BEAM), a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON Phase 1/2 trial of BEAM-101 at the European Hematology Association 2025 Congress, June 12-15 in Milan. BEAM-101 is an investigational, one-time ex vivo cell therapy targeting severe vaso-occlusive crises in sickle cell disease (SCD). The new data, covering safety and efficacy outcomes in 17 patients, will be highlighted during multiple poster sessions on June 13, underscoring BEAM-101’s potential to provide a durable treatment by addressing the root cause of SCD. Additional presentations will explore biomarkers, manufacturing advances, and red blood cell health post-treatment. Beam will also host a webcast on June 13 at 4:00 p.m. ET to review EHA highlights. To view the full press release, visit https://nnw.fm/taUAe About Beam Therapeutics Beam Therapeutics (NASDAQ: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines

INACTIVE